CHEK2 Antikörper (AA 481-531)
-
- Target Alle CHEK2 Antikörper anzeigen
- CHEK2 (Checkpoint Kinase 2 (CHEK2))
-
Bindungsspezifität
- AA 481-531
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser CHEK2 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)
- Verwendungszweck
- CHK2 Antibody
- Aufreinigung
- Ascitic fluid
- Immunogen
- Purified recombinant fragment of human CHK2 (aa481-531) expressed in E. Coli.
- Klon
- 1C12B8
- Isotyp
- IgG2b
- Top Product
- Discover our top product CHEK2 Primärantikörper
-
-
- Applikationshinweise
-
ELISA: 1/10000
ICC: 1/200 - 1/1000
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Ascitic fluid containing 0.03 % sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
-
-
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. ..." in: Carcinogenesis, Vol. 29, Issue 4, pp. 762-5, (2008) (PubMed).
: "CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?" in: Nature reviews. Cancer, Vol. 7, Issue 12, pp. 925-36, (2007) (PubMed).
: "Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts." in: International journal of cancer. Journal international du cancer, Vol. 121, Issue 12, pp. 2661-7, (2007) (PubMed).
: "
-
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. ..." in: Carcinogenesis, Vol. 29, Issue 4, pp. 762-5, (2008) (PubMed).
-
- Target
- CHEK2 (Checkpoint Kinase 2 (CHEK2))
- Andere Bezeichnung
- CHK2 (CHEK2 Produkte)
- Synonyme
- CDS1 antikoerper, CHK2 antikoerper, HuCds1 antikoerper, LFS2 antikoerper, PP1425 antikoerper, RAD53 antikoerper, hCds1 antikoerper, fa66f08 antikoerper, wu:fa66f08 antikoerper, zgc:55865 antikoerper, Cds1 antikoerper, HUCDS1 antikoerper, Rad53 antikoerper, Chk2 antikoerper, cds1 antikoerper, chek2 antikoerper, chk2 antikoerper, hucds1 antikoerper, lfs2 antikoerper, pp1425 antikoerper, rad53 antikoerper, checkpoint kinase 2 antikoerper, serine/threonine-protein kinase chk2 antikoerper, checkpoint kinase 2 L homeolog antikoerper, CHEK2 antikoerper, chek2 antikoerper, Chek2 antikoerper, MCYG_07308 antikoerper, chek2.L antikoerper
- Hintergrund
-
Description: CHK2: CHK2 checkpoint homolog (S. pombe). In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.
Aliases: CDS1, LFS2, CHEK2
- Molekulargewicht
- 61kDa
- Gen-ID
- 11200
- HGNC
- 11200
- UniProt
- O96017
- Pathways
- p53 Signalweg, Apoptose, Zellzyklus
-